Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy - Wikidata - awgldk - TriplyDB

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

http://www.wikidata.org/entity/Q33775549

about

The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer.Redefining hormone resistance in prostate cancer.5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression.Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy.Update on the management of prostate cancer with goserelin acetate: patient perspectives Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer.Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.An update on the changing indications for androgen deprivation therapy for prostate cancer.Emerging drugs for prostate cancer.The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.5α-reductase type 3 enzyme in benign and malignant prostate.Cholesterol as a potential target for castration-resistant prostate cancer.Androgen suppression strategies for prostate cancer: is there an ideal approach?The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.The role of abiraterone in the management of metastatic castration-resistant prostate cancer.Concept and viability of androgen annihilation for advanced prostate cancer.SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization.Androgen synthesis in prostate cancer: do all roads lead to Rome?Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer.Androgen Signaling in Prostate Cancer.Castration-resistant prostate cancer: targeted therapies and individualized treatment A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer Clinical implications of the 5α-androstanedione pathway for castration-resistant prostate cancer.Leveraging the species barrier to advance cancer therapy.Inhibition of dihydrotestosterone synthesis in prostate cancer by combined frontdoor and backdoor pathway blockade.

P2860

Q21285041-08DE8101-CA26-41CC-ADBB-80847D3D261D Q27007208-6EA11353-CC93-4E37-8C0B-906606F5E4DF Q33446864-5A7A4BF5-9CB9-4EA6-ADBB-C58D0E3C67A9 Q33903836-2BC4CA4D-F32D-431B-8412-AAC54B34482C Q34183936-70522556-66DE-4DFF-B67E-77C33852B2B3 Q34204078-48ED3425-26D2-41EA-94BC-FDAD2A4B6A3B Q34294888-CB819122-1705-4476-B292-AE68E9712465 Q34418403-708AA679-4473-43CD-AAFB-8D7B2DFB53A0 Q34619574-1FD7576E-3A10-4687-B700-9648B98BA41D Q35223874-087513B9-8988-40D1-854C-24346CDDC2DF Q35549863-5FC0142E-F5E2-411F-B534-09867EC79733 Q37570555-8E9CDCCB-B898-40CA-B8F1-B8725EA0CB5F Q37709925-DC212FA5-1476-44D6-B259-BCF7756A737F Q37712234-CF344DAB-D7C0-4BBE-9630-02B97AB7D954 Q37777663-75509031-B1C7-4CAA-9F61-DA60E7A79FBB Q37850714-5387D11A-3E40-4664-ABA7-9CB8C9D61C9E Q37953805-1D118545-2781-4BC6-8C2B-A0A03C42CC7C Q38002465-3B0BEB37-2440-41C7-B3B8-6949FA0159E8 Q38207556-6F06B63D-24AF-4B46-9111-20074B729374 Q38862028-40C78DEF-112C-4536-8B95-40B40F5A5804 Q39002780-4AEF3699-21A0-435B-BDAB-9DFB4BF1977D Q39176498-FA04B8C9-28DF-4BCB-9874-2B5929362171 Q39227656-6EF248DD-516B-4121-9C59-D33AA582A5E6 Q39511732-32BECCED-1264-432C-A024-ED3B7B406301 Q42174990-6EBF45F0-FD96-4CD2-AFD6-28A709BDB3F4 Q44938966-C63FC5C9-CCAD-4181-B132-4FBF608EA339 Q45758959-506DD535-F6FC-46B6-AF97-E6D2C7247C4E Q52655045-E6C415DF-E6B9-498C-9010-BDCC32956376

P2860

Phase II study of Dutasteride for recurrent prostate cancer during androgen deprivation therapy

http://www.wikidata.org/entity/Q33775549

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase II study of Dutasteride ...... g androgen deprivation therapy

@ast

Phase II study of Dutasteride ...... g androgen deprivation therapy

@en

type

label

Phase II study of Dutasteride ...... g androgen deprivation therapy

@ast

Phase II study of Dutasteride ...... g androgen deprivation therapy

@en

prefLabel

Phase II study of Dutasteride ...... g androgen deprivation therapy

@ast

Phase II study of Dutasteride ...... g androgen deprivation therapy

@en

P1433

Q33775549-5C54D58B-0724-43DD-ABFC-27EEA72C61B1

P1476

Q33775549-733DCB1B-AE93-4604-992A-24B5ABFE5C1C

P2093

Q33775549-0C418035-F5E7-4491-954A-BAE76EE5242B

Q33775549-0DBD8D2B-6EB3-42F8-A32D-5F0CC8F4DFEF

Q33775549-0F2F6CBE-0B17-48F8-9C1B-41A082336D40

Q33775549-3B6B4D02-B18E-42EB-A8F5-54350FE5BE09

Q33775549-6D0E80D5-1D65-48D3-94A3-5C589D8A4458

Q33775549-EE61B249-2A1D-432B-95EC-529F415D60CD

P2860

Q33775549-0581E48C-FF25-4A8D-82AE-7CC29717D4BC

Q33775549-061149AD-0C45-41C4-817A-44FC49FB7732

Q33775549-09120EEC-0CC9-46CF-AE25-112C157FEB5E

Q33775549-1BBAF79C-FA3D-42A3-8998-0701315191C1

Q33775549-1D5CF87E-F49B-48BE-8F65-4AC39507CF73

Q33775549-24727CA6-1476-481E-90BF-9CD3C46F7194

Q33775549-334F2655-651F-4224-8380-57C9E90099F3

Q33775549-467A2A25-982A-46B2-B7AA-F45975119D4D

Q33775549-4DCD63D3-EA89-470D-A950-2416AF9078BE

Q33775549-62E7BB56-710B-4B31-B7DB-181471BD9747

P304

Q33775549-C19330B8-DB55-47E4-BC48-A81A24BCC533

P31

Q33775549-4C9C2CBE-C20A-4B6D-B6C1-386D9C2E5848

P356

Q33775549-8B3EE127-4D1F-4AC7-BAB9-C948EABE498C

P407

Q33775549-17C759EB-9762-4DC2-88AA-D9ECC6C837A4

P433

Q33775549-BC260647-7C12-4A49-850A-594C9976E8E3

P478

Q33775549-6C29940A-BA7C-4C83-AD3B-6C59EB4C6191

P577

Q33775549-EB59A750-2BE0-4D4C-8FD1-8C0BCFB8BBED

P5875

Q33775549-7F7356D7-6AEF-4BCA-9E6D-8E94952B660C

P698

Q33775549-80AF3676-A218-4036-AF2A-B2D93AB3FF9B

P932

Q33775549-3F446D4D-59E1-42A5-B76B-662608B1CE8F

P356

J.JURO.2008.10.014

P1433

The Journal of Urology

P1476

Phase II study of Dutasteride ...... g androgen deprivation therapy

@en

P2093

Donald L Trump

http://www.w3.org/2001/XMLSchema#string

Gregory E Wilding

http://www.w3.org/2001/XMLSchema#string

James L Mohler

http://www.w3.org/2001/XMLSchema#string

Oliver Sartor

http://www.w3.org/2001/XMLSchema#string

Satyan K Shah

http://www.w3.org/2001/XMLSchema#string

Wei Tan

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer.

Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status.

Secondary hormonal therapy for advanced prostate cancer.

How effective is cytotoxic chemotherapy for disseminated prostatic carcinoma?

The androgen axis in recurrent prostate cancer.

P304

621-626

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2008.10.014

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

181

http://www.w3.org/2001/XMLSchema#string

P577

2008-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23672398

http://www.w3.org/2001/XMLSchema#string

P698

19091347

http://www.w3.org/2001/XMLSchema#string

P932

2851185

http://www.w3.org/2001/XMLSchema#string